Global Rheumatology Drugs
Global Rheumatology Drugs

Rheumatology Drugs Comprehensive Study by Type (Disease Modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Others), Application (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Drug Type (Hydroxychloroquine (Plaquenil), Leflunomide (Arava), Methotrexate (Trexall), Sulfasalazine (Azulfidine), Minocycline (Minocin), Others), Route of Administration (Oral, Parenteral) Players and Region - Global Market Outlook to 2025

Rheumatology Drugs Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Dec 2020 Edition 233 Pages 210 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Rheumatology Drugs Market Scope?
Rheumatoid arthritis is a disease that causes pain and inflammation in the joints. It affects people of all ages. However, the geriatric population is very susceptible to developing this disease. The symptoms of rheumatoid arthritis are pain, stiffness, tenderness, and swelling of the joints. Rheumatoid arthritis affects approximately 1% of the world's population. The condition presents various symptoms such as joint pain, swelling, and stiffness, which are generally accompanied by chronic pain and the inability to perform daily activities. Over a long period of time, this disorder can impair a patient's mobility and lead to permanent joint damage. If left untreated, this disorder can lead to impaired mobility and the risk of joint replacement. There is currently no cure for rheumatoid arthritis available. However, certain drugs are used to efficiently control rheumatoid arthritis conditions, including disease-modifying anti-inflammatory drugs (DMARDs), nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and uric acid drugs.

The Rheumatology Drugs market study is being classified by Type (Disease Modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs and Others), by Application (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy) and major geographies with country level break-up.

The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that Players from United States will contribute to the maximum growth of Global Rheumatology Drugs market throughout the predicted period.

Takeda Pharmaceutical Company (Japan), Sanofi (France), Genentech (United States), Eli Lilly and Company (United States), AbbVie Inc. (United States), Pfizer (United States), Bristol-Myers Squibb Company (United States), Novartis (Switzerland), Boehringer Ingelheim GmbH (Germany), Janssen Biotech (United States), Regeneron Pharmaceuticals, Inc. (United States), F. Hoffmann-La Roche Ltd. (Switzerland) and Amgen Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Merck & Co., Inc. (United States) and UCB S.A. (Belgium).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Rheumatology Drugs market by Type, Application and Region.

On the basis of geography, the market of Rheumatology Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Influencing Market Trend
  • A Rise in Awareness Related To Early Screening and Treatment of Rheumatoid Arthritis
  • The Rise in Awareness Related To the Use of DMARDs
  • Increase in Adoption of DMARDs as a First-Line Treatment for Rheumatoid Arthritis
  • Improvement in Buying Power, And Access to Quality Drugs to Poor & Middle-Class Families

Market Drivers
  • A Rise in Prevalence of Rheumatoid Arthritis
  • The Surge in Geriatric Population
  • The Rise in Obese & Overweight Population across the Globe
  • Increase in Demand for Rheumatoid Arthritis Drugs
  • Expiration of Patents & the Entry of Biosimilar Drugs

Opportunities
  • Increase in Adoption of Conventional DMARDs
  • Innovations in Advanced Biologics
  • A Rise in Healthcare Expenditure
  • Government Initiatives toward Spread in Awareness for Rheumatoid Arthritis Symptoms

Restraints
  • Side Effects Associated With the Medication

Challenges
  • High Costs of Biological DMARD Therapies


Key Target Audience
Manufacturers of Rheumatology Drugs, Suppliers and Distributors of Rheumatology Drugs, End-Users, Potential Investors, Market Research Firms and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.
Report Objectives / Segmentation Covered
By Type
  • Disease Modifying Anti-rheumatic Drugs
  • Nonsteroidal Anti-inflammatory Drugs
  • Corticosteroids
  • Uric Acid Drugs
  • Others
By Application
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
By Drug Type
  • Hydroxychloroquine (Plaquenil)
  • Leflunomide (Arava)
  • Methotrexate (Trexall)
  • Sulfasalazine (Azulfidine)
  • Minocycline (Minocin)
  • Others

By Route of Administration
  • Oral
  • Parenteral

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. A Rise in Prevalence of Rheumatoid Arthritis
      • 3.2.2. The Surge in Geriatric Population
      • 3.2.3. The Rise in Obese & Overweight Population across the Globe
      • 3.2.4. Increase in Demand for Rheumatoid Arthritis Drugs
      • 3.2.5. Expiration of Patents & the Entry of Biosimilar Drugs
    • 3.3. Market Challenges
      • 3.3.1. High Costs of Biological DMARD Therapies
    • 3.4. Market Trends
      • 3.4.1. A Rise in Awareness Related To Early Screening and Treatment of Rheumatoid Arthritis
      • 3.4.2. The Rise in Awareness Related To the Use of DMARDs
      • 3.4.3. Increase in Adoption of DMARDs as a First-Line Treatment for Rheumatoid Arthritis
      • 3.4.4. Improvement in Buying Power, And Access to Quality Drugs to Poor & Middle-Class Families
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Rheumatology Drugs, by Type, Application, Drug Type, Route of Administration and Region (value, volume and price ) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Rheumatology Drugs (Value)
      • 5.2.1. Global Rheumatology Drugs by: Type (Value)
        • 5.2.1.1. Disease Modifying Anti-rheumatic Drugs
        • 5.2.1.2. Nonsteroidal Anti-inflammatory Drugs
        • 5.2.1.3. Corticosteroids
        • 5.2.1.4. Uric Acid Drugs
        • 5.2.1.5. Others
      • 5.2.2. Global Rheumatology Drugs by: Application (Value)
        • 5.2.2.1. Hospital Pharmacy
        • 5.2.2.2. Retail Pharmacy
        • 5.2.2.3. Online Pharmacy
      • 5.2.3. Global Rheumatology Drugs by: Drug Type (Value)
        • 5.2.3.1. Hydroxychloroquine (Plaquenil)
        • 5.2.3.2. Leflunomide (Arava)
        • 5.2.3.3. Methotrexate (Trexall)
        • 5.2.3.4. Sulfasalazine (Azulfidine)
        • 5.2.3.5. Minocycline (Minocin)
        • 5.2.3.6. Others
      • 5.2.4. Global Rheumatology Drugs by: Route of Administration (Value)
        • 5.2.4.1. Oral
        • 5.2.4.2. Parenteral
      • 5.2.5. Global Rheumatology Drugs Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Rheumatology Drugs (Volume)
      • 5.3.1. Global Rheumatology Drugs by: Type (Volume)
        • 5.3.1.1. Disease Modifying Anti-rheumatic Drugs
        • 5.3.1.2. Nonsteroidal Anti-inflammatory Drugs
        • 5.3.1.3. Corticosteroids
        • 5.3.1.4. Uric Acid Drugs
        • 5.3.1.5. Others
      • 5.3.2. Global Rheumatology Drugs by: Application (Volume)
        • 5.3.2.1. Hospital Pharmacy
        • 5.3.2.2. Retail Pharmacy
        • 5.3.2.3. Online Pharmacy
      • 5.3.3. Global Rheumatology Drugs by: Drug Type (Volume)
        • 5.3.3.1. Hydroxychloroquine (Plaquenil)
        • 5.3.3.2. Leflunomide (Arava)
        • 5.3.3.3. Methotrexate (Trexall)
        • 5.3.3.4. Sulfasalazine (Azulfidine)
        • 5.3.3.5. Minocycline (Minocin)
        • 5.3.3.6. Others
      • 5.3.4. Global Rheumatology Drugs by: Route of Administration (Volume)
        • 5.3.4.1. Oral
        • 5.3.4.2. Parenteral
      • 5.3.5. Global Rheumatology Drugs Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Taiwan
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Rheumatology Drugs (Price)
      • 5.4.1. Global Rheumatology Drugs by: Type (Price)
  • 6. Rheumatology Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Takeda Pharmaceutical Company (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Genentech (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eli Lilly and Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AbbVie Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Bristol-Myers Squibb Company (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Boehringer Ingelheim GmbH (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Janssen Biotech (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Regeneron Pharmaceuticals, Inc. (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Amgen Inc. (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Rheumatology Drugs Sale, by Type, Application, Drug Type, Route of Administration and Region (value, volume and price ) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Rheumatology Drugs (Value)
      • 7.2.1. Global Rheumatology Drugs by: Type (Value)
        • 7.2.1.1. Disease Modifying Anti-rheumatic Drugs
        • 7.2.1.2. Nonsteroidal Anti-inflammatory Drugs
        • 7.2.1.3. Corticosteroids
        • 7.2.1.4. Uric Acid Drugs
        • 7.2.1.5. Others
      • 7.2.2. Global Rheumatology Drugs by: Application (Value)
        • 7.2.2.1. Hospital Pharmacy
        • 7.2.2.2. Retail Pharmacy
        • 7.2.2.3. Online Pharmacy
      • 7.2.3. Global Rheumatology Drugs by: Drug Type (Value)
        • 7.2.3.1. Hydroxychloroquine (Plaquenil)
        • 7.2.3.2. Leflunomide (Arava)
        • 7.2.3.3. Methotrexate (Trexall)
        • 7.2.3.4. Sulfasalazine (Azulfidine)
        • 7.2.3.5. Minocycline (Minocin)
        • 7.2.3.6. Others
      • 7.2.4. Global Rheumatology Drugs by: Route of Administration (Value)
        • 7.2.4.1. Oral
        • 7.2.4.2. Parenteral
      • 7.2.5. Global Rheumatology Drugs Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Rheumatology Drugs (Volume)
      • 7.3.1. Global Rheumatology Drugs by: Type (Volume)
        • 7.3.1.1. Disease Modifying Anti-rheumatic Drugs
        • 7.3.1.2. Nonsteroidal Anti-inflammatory Drugs
        • 7.3.1.3. Corticosteroids
        • 7.3.1.4. Uric Acid Drugs
        • 7.3.1.5. Others
      • 7.3.2. Global Rheumatology Drugs by: Application (Volume)
        • 7.3.2.1. Hospital Pharmacy
        • 7.3.2.2. Retail Pharmacy
        • 7.3.2.3. Online Pharmacy
      • 7.3.3. Global Rheumatology Drugs by: Drug Type (Volume)
        • 7.3.3.1. Hydroxychloroquine (Plaquenil)
        • 7.3.3.2. Leflunomide (Arava)
        • 7.3.3.3. Methotrexate (Trexall)
        • 7.3.3.4. Sulfasalazine (Azulfidine)
        • 7.3.3.5. Minocycline (Minocin)
        • 7.3.3.6. Others
      • 7.3.4. Global Rheumatology Drugs by: Route of Administration (Volume)
        • 7.3.4.1. Oral
        • 7.3.4.2. Parenteral
      • 7.3.5. Global Rheumatology Drugs Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Taiwan
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Rheumatology Drugs (Price)
      • 7.4.1. Global Rheumatology Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Rheumatology Drugs: by Type(USD Million)
  • Table 2. Rheumatology Drugs Disease Modifying Anti-rheumatic Drugs , by Region USD Million (2014-2019)
  • Table 3. Rheumatology Drugs Nonsteroidal Anti-inflammatory Drugs , by Region USD Million (2014-2019)
  • Table 4. Rheumatology Drugs Corticosteroids , by Region USD Million (2014-2019)
  • Table 5. Rheumatology Drugs Uric Acid Drugs , by Region USD Million (2014-2019)
  • Table 6. Rheumatology Drugs Others , by Region USD Million (2014-2019)
  • Table 7. Rheumatology Drugs: by Application(USD Million)
  • Table 8. Rheumatology Drugs Hospital Pharmacy , by Region USD Million (2014-2019)
  • Table 9. Rheumatology Drugs Retail Pharmacy , by Region USD Million (2014-2019)
  • Table 10. Rheumatology Drugs Online Pharmacy , by Region USD Million (2014-2019)
  • Table 11. Rheumatology Drugs: by Drug Type(USD Million)
  • Table 12. Rheumatology Drugs Hydroxychloroquine (Plaquenil) , by Region USD Million (2014-2019)
  • Table 13. Rheumatology Drugs Leflunomide (Arava) , by Region USD Million (2014-2019)
  • Table 14. Rheumatology Drugs Methotrexate (Trexall) , by Region USD Million (2014-2019)
  • Table 15. Rheumatology Drugs Sulfasalazine (Azulfidine) , by Region USD Million (2014-2019)
  • Table 16. Rheumatology Drugs Minocycline (Minocin) , by Region USD Million (2014-2019)
  • Table 17. Rheumatology Drugs Others , by Region USD Million (2014-2019)
  • Table 18. Rheumatology Drugs: by Route of Administration(USD Million)
  • Table 19. Rheumatology Drugs Oral , by Region USD Million (2014-2019)
  • Table 20. Rheumatology Drugs Parenteral , by Region USD Million (2014-2019)
  • Table 21. South America Rheumatology Drugs, by Country USD Million (2014-2019)
  • Table 22. South America Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 23. South America Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 24. South America Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 25. South America Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 26. Brazil Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 27. Brazil Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 28. Brazil Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 29. Brazil Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 30. Argentina Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 31. Argentina Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 32. Argentina Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 33. Argentina Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 34. Rest of South America Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 35. Rest of South America Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 36. Rest of South America Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 37. Rest of South America Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 38. Asia Pacific Rheumatology Drugs, by Country USD Million (2014-2019)
  • Table 39. Asia Pacific Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 40. Asia Pacific Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 41. Asia Pacific Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 42. Asia Pacific Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 43. China Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 44. China Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 45. China Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 46. China Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 47. Japan Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 48. Japan Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 49. Japan Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 50. Japan Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 51. India Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 52. India Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 53. India Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 54. India Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 55. South Korea Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 56. South Korea Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 57. South Korea Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 58. South Korea Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 59. Taiwan Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 60. Taiwan Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 61. Taiwan Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 62. Taiwan Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 63. Australia Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 64. Australia Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 65. Australia Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 66. Australia Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 67. Rest of Asia-Pacific Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 68. Rest of Asia-Pacific Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 69. Rest of Asia-Pacific Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 70. Rest of Asia-Pacific Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 71. Europe Rheumatology Drugs, by Country USD Million (2014-2019)
  • Table 72. Europe Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 73. Europe Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 74. Europe Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 75. Europe Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 76. Germany Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 77. Germany Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 78. Germany Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 79. Germany Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 80. France Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 81. France Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 82. France Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 83. France Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 84. Italy Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 85. Italy Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 86. Italy Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 87. Italy Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 88. United Kingdom Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 89. United Kingdom Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 90. United Kingdom Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 91. United Kingdom Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 92. Netherlands Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 93. Netherlands Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 94. Netherlands Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 95. Netherlands Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 96. Rest of Europe Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 97. Rest of Europe Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 98. Rest of Europe Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 99. Rest of Europe Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 100. MEA Rheumatology Drugs, by Country USD Million (2014-2019)
  • Table 101. MEA Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 102. MEA Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 103. MEA Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 104. MEA Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 105. Middle East Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 106. Middle East Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 107. Middle East Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 108. Middle East Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 109. Africa Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 110. Africa Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 111. Africa Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 112. Africa Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 113. North America Rheumatology Drugs, by Country USD Million (2014-2019)
  • Table 114. North America Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 115. North America Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 116. North America Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 117. North America Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 118. United States Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 119. United States Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 120. United States Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 121. United States Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 122. Canada Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 123. Canada Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 124. Canada Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 125. Canada Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 126. Mexico Rheumatology Drugs, by Type USD Million (2014-2019)
  • Table 127. Mexico Rheumatology Drugs, by Application USD Million (2014-2019)
  • Table 128. Mexico Rheumatology Drugs, by Drug Type USD Million (2014-2019)
  • Table 129. Mexico Rheumatology Drugs, by Route of Administration USD Million (2014-2019)
  • Table 130. Rheumatology Drugs Sales: by Type(K Tons)
  • Table 131. Rheumatology Drugs Sales Disease Modifying Anti-rheumatic Drugs , by Region K Tons (2014-2019)
  • Table 132. Rheumatology Drugs Sales Nonsteroidal Anti-inflammatory Drugs , by Region K Tons (2014-2019)
  • Table 133. Rheumatology Drugs Sales Corticosteroids , by Region K Tons (2014-2019)
  • Table 134. Rheumatology Drugs Sales Uric Acid Drugs , by Region K Tons (2014-2019)
  • Table 135. Rheumatology Drugs Sales Others , by Region K Tons (2014-2019)
  • Table 136. Rheumatology Drugs Sales: by Application(K Tons)
  • Table 137. Rheumatology Drugs Sales Hospital Pharmacy , by Region K Tons (2014-2019)
  • Table 138. Rheumatology Drugs Sales Retail Pharmacy , by Region K Tons (2014-2019)
  • Table 139. Rheumatology Drugs Sales Online Pharmacy , by Region K Tons (2014-2019)
  • Table 140. Rheumatology Drugs Sales: by Drug Type(K Tons)
  • Table 141. Rheumatology Drugs Sales Hydroxychloroquine (Plaquenil) , by Region K Tons (2014-2019)
  • Table 142. Rheumatology Drugs Sales Leflunomide (Arava) , by Region K Tons (2014-2019)
  • Table 143. Rheumatology Drugs Sales Methotrexate (Trexall) , by Region K Tons (2014-2019)
  • Table 144. Rheumatology Drugs Sales Sulfasalazine (Azulfidine) , by Region K Tons (2014-2019)
  • Table 145. Rheumatology Drugs Sales Minocycline (Minocin) , by Region K Tons (2014-2019)
  • Table 146. Rheumatology Drugs Sales Others , by Region K Tons (2014-2019)
  • Table 147. Rheumatology Drugs Sales: by Route of Administration(K Tons)
  • Table 148. Rheumatology Drugs Sales Oral , by Region K Tons (2014-2019)
  • Table 149. Rheumatology Drugs Sales Parenteral , by Region K Tons (2014-2019)
  • Table 150. South America Rheumatology Drugs Sales, by Country K Tons (2014-2019)
  • Table 151. South America Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 152. South America Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 153. South America Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 154. South America Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 155. Brazil Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 156. Brazil Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 157. Brazil Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 158. Brazil Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 159. Argentina Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 160. Argentina Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 161. Argentina Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 162. Argentina Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 163. Rest of South America Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 164. Rest of South America Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 165. Rest of South America Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 166. Rest of South America Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 167. Asia Pacific Rheumatology Drugs Sales, by Country K Tons (2014-2019)
  • Table 168. Asia Pacific Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 169. Asia Pacific Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 170. Asia Pacific Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 171. Asia Pacific Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 172. China Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 173. China Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 174. China Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 175. China Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 176. Japan Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 177. Japan Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 178. Japan Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 179. Japan Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 180. India Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 181. India Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 182. India Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 183. India Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 184. South Korea Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 185. South Korea Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 186. South Korea Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 187. South Korea Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 188. Taiwan Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 189. Taiwan Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 190. Taiwan Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 191. Taiwan Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 192. Australia Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 193. Australia Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 194. Australia Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 195. Australia Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 196. Rest of Asia-Pacific Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 197. Rest of Asia-Pacific Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 198. Rest of Asia-Pacific Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 199. Rest of Asia-Pacific Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 200. Europe Rheumatology Drugs Sales, by Country K Tons (2014-2019)
  • Table 201. Europe Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 202. Europe Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 203. Europe Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 204. Europe Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 205. Germany Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 206. Germany Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 207. Germany Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 208. Germany Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 209. France Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 210. France Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 211. France Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 212. France Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 213. Italy Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 214. Italy Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 215. Italy Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 216. Italy Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 217. United Kingdom Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 218. United Kingdom Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 219. United Kingdom Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 220. United Kingdom Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 221. Netherlands Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 222. Netherlands Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 223. Netherlands Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 224. Netherlands Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 225. Rest of Europe Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 226. Rest of Europe Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 227. Rest of Europe Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 228. Rest of Europe Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 229. MEA Rheumatology Drugs Sales, by Country K Tons (2014-2019)
  • Table 230. MEA Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 231. MEA Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 232. MEA Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 233. MEA Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 234. Middle East Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 235. Middle East Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 236. Middle East Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 237. Middle East Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 238. Africa Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 239. Africa Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 240. Africa Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 241. Africa Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 242. North America Rheumatology Drugs Sales, by Country K Tons (2014-2019)
  • Table 243. North America Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 244. North America Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 245. North America Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 246. North America Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 247. United States Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 248. United States Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 249. United States Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 250. United States Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 251. Canada Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 252. Canada Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 253. Canada Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 254. Canada Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 255. Mexico Rheumatology Drugs Sales, by Type K Tons (2014-2019)
  • Table 256. Mexico Rheumatology Drugs Sales, by Application K Tons (2014-2019)
  • Table 257. Mexico Rheumatology Drugs Sales, by Drug Type K Tons (2014-2019)
  • Table 258. Mexico Rheumatology Drugs Sales, by Route of Administration K Tons (2014-2019)
  • Table 259. Rheumatology Drugs: by Type(USD/Units)
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Company Basic Information, Sales Area and Its Competitors
  • Table 269. Company Basic Information, Sales Area and Its Competitors
  • Table 270. Company Basic Information, Sales Area and Its Competitors
  • Table 271. Company Basic Information, Sales Area and Its Competitors
  • Table 272. Company Basic Information, Sales Area and Its Competitors
  • Table 273. Rheumatology Drugs: by Type(USD Million)
  • Table 274. Rheumatology Drugs Disease Modifying Anti-rheumatic Drugs , by Region USD Million (2020-2025)
  • Table 275. Rheumatology Drugs Nonsteroidal Anti-inflammatory Drugs , by Region USD Million (2020-2025)
  • Table 276. Rheumatology Drugs Corticosteroids , by Region USD Million (2020-2025)
  • Table 277. Rheumatology Drugs Uric Acid Drugs , by Region USD Million (2020-2025)
  • Table 278. Rheumatology Drugs Others , by Region USD Million (2020-2025)
  • Table 279. Rheumatology Drugs: by Application(USD Million)
  • Table 280. Rheumatology Drugs Hospital Pharmacy , by Region USD Million (2020-2025)
  • Table 281. Rheumatology Drugs Retail Pharmacy , by Region USD Million (2020-2025)
  • Table 282. Rheumatology Drugs Online Pharmacy , by Region USD Million (2020-2025)
  • Table 283. Rheumatology Drugs: by Drug Type(USD Million)
  • Table 284. Rheumatology Drugs Hydroxychloroquine (Plaquenil) , by Region USD Million (2020-2025)
  • Table 285. Rheumatology Drugs Leflunomide (Arava) , by Region USD Million (2020-2025)
  • Table 286. Rheumatology Drugs Methotrexate (Trexall) , by Region USD Million (2020-2025)
  • Table 287. Rheumatology Drugs Sulfasalazine (Azulfidine) , by Region USD Million (2020-2025)
  • Table 288. Rheumatology Drugs Minocycline (Minocin) , by Region USD Million (2020-2025)
  • Table 289. Rheumatology Drugs Others , by Region USD Million (2020-2025)
  • Table 290. Rheumatology Drugs: by Route of Administration(USD Million)
  • Table 291. Rheumatology Drugs Oral , by Region USD Million (2020-2025)
  • Table 292. Rheumatology Drugs Parenteral , by Region USD Million (2020-2025)
  • Table 293. South America Rheumatology Drugs, by Country USD Million (2020-2025)
  • Table 294. South America Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 295. South America Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 296. South America Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 297. South America Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 298. Brazil Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 299. Brazil Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 300. Brazil Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 301. Brazil Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 302. Argentina Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 303. Argentina Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 304. Argentina Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 305. Argentina Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 306. Rest of South America Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 307. Rest of South America Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 308. Rest of South America Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 309. Rest of South America Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 310. Asia Pacific Rheumatology Drugs, by Country USD Million (2020-2025)
  • Table 311. Asia Pacific Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 312. Asia Pacific Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 313. Asia Pacific Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 314. Asia Pacific Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 315. China Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 316. China Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 317. China Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 318. China Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 319. Japan Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 320. Japan Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 321. Japan Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 322. Japan Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 323. India Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 324. India Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 325. India Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 326. India Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 327. South Korea Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 328. South Korea Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 329. South Korea Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 330. South Korea Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 331. Taiwan Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 332. Taiwan Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 333. Taiwan Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 334. Taiwan Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 335. Australia Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 336. Australia Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 337. Australia Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 338. Australia Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 339. Rest of Asia-Pacific Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 340. Rest of Asia-Pacific Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 341. Rest of Asia-Pacific Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 342. Rest of Asia-Pacific Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 343. Europe Rheumatology Drugs, by Country USD Million (2020-2025)
  • Table 344. Europe Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 345. Europe Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 346. Europe Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 347. Europe Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 348. Germany Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 349. Germany Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 350. Germany Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 351. Germany Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 352. France Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 353. France Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 354. France Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 355. France Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 356. Italy Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 357. Italy Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 358. Italy Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 359. Italy Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 360. United Kingdom Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 361. United Kingdom Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 362. United Kingdom Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 363. United Kingdom Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 364. Netherlands Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 365. Netherlands Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 366. Netherlands Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 367. Netherlands Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 368. Rest of Europe Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 369. Rest of Europe Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 370. Rest of Europe Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 371. Rest of Europe Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 372. MEA Rheumatology Drugs, by Country USD Million (2020-2025)
  • Table 373. MEA Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 374. MEA Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 375. MEA Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 376. MEA Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 377. Middle East Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 378. Middle East Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 379. Middle East Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 380. Middle East Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 381. Africa Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 382. Africa Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 383. Africa Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 384. Africa Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 385. North America Rheumatology Drugs, by Country USD Million (2020-2025)
  • Table 386. North America Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 387. North America Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 388. North America Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 389. North America Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 390. United States Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 391. United States Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 392. United States Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 393. United States Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 394. Canada Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 395. Canada Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 396. Canada Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 397. Canada Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 398. Mexico Rheumatology Drugs, by Type USD Million (2020-2025)
  • Table 399. Mexico Rheumatology Drugs, by Application USD Million (2020-2025)
  • Table 400. Mexico Rheumatology Drugs, by Drug Type USD Million (2020-2025)
  • Table 401. Mexico Rheumatology Drugs, by Route of Administration USD Million (2020-2025)
  • Table 402. Rheumatology Drugs Sales: by Type(K Tons)
  • Table 403. Rheumatology Drugs Sales Disease Modifying Anti-rheumatic Drugs , by Region K Tons (2020-2025)
  • Table 404. Rheumatology Drugs Sales Nonsteroidal Anti-inflammatory Drugs , by Region K Tons (2020-2025)
  • Table 405. Rheumatology Drugs Sales Corticosteroids , by Region K Tons (2020-2025)
  • Table 406. Rheumatology Drugs Sales Uric Acid Drugs , by Region K Tons (2020-2025)
  • Table 407. Rheumatology Drugs Sales Others , by Region K Tons (2020-2025)
  • Table 408. Rheumatology Drugs Sales: by Application(K Tons)
  • Table 409. Rheumatology Drugs Sales Hospital Pharmacy , by Region K Tons (2020-2025)
  • Table 410. Rheumatology Drugs Sales Retail Pharmacy , by Region K Tons (2020-2025)
  • Table 411. Rheumatology Drugs Sales Online Pharmacy , by Region K Tons (2020-2025)
  • Table 412. Rheumatology Drugs Sales: by Drug Type(K Tons)
  • Table 413. Rheumatology Drugs Sales Hydroxychloroquine (Plaquenil) , by Region K Tons (2020-2025)
  • Table 414. Rheumatology Drugs Sales Leflunomide (Arava) , by Region K Tons (2020-2025)
  • Table 415. Rheumatology Drugs Sales Methotrexate (Trexall) , by Region K Tons (2020-2025)
  • Table 416. Rheumatology Drugs Sales Sulfasalazine (Azulfidine) , by Region K Tons (2020-2025)
  • Table 417. Rheumatology Drugs Sales Minocycline (Minocin) , by Region K Tons (2020-2025)
  • Table 418. Rheumatology Drugs Sales Others , by Region K Tons (2020-2025)
  • Table 419. Rheumatology Drugs Sales: by Route of Administration(K Tons)
  • Table 420. Rheumatology Drugs Sales Oral , by Region K Tons (2020-2025)
  • Table 421. Rheumatology Drugs Sales Parenteral , by Region K Tons (2020-2025)
  • Table 422. South America Rheumatology Drugs Sales, by Country K Tons (2020-2025)
  • Table 423. South America Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 424. South America Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 425. South America Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 426. South America Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 427. Brazil Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 428. Brazil Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 429. Brazil Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 430. Brazil Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 431. Argentina Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 432. Argentina Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 433. Argentina Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 434. Argentina Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 435. Rest of South America Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 436. Rest of South America Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 437. Rest of South America Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 438. Rest of South America Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 439. Asia Pacific Rheumatology Drugs Sales, by Country K Tons (2020-2025)
  • Table 440. Asia Pacific Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 441. Asia Pacific Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 442. Asia Pacific Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 443. Asia Pacific Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 444. China Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 445. China Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 446. China Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 447. China Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 448. Japan Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 449. Japan Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 450. Japan Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 451. Japan Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 452. India Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 453. India Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 454. India Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 455. India Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 456. South Korea Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 457. South Korea Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 458. South Korea Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 459. South Korea Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 460. Taiwan Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 461. Taiwan Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 462. Taiwan Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 463. Taiwan Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 464. Australia Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 465. Australia Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 466. Australia Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 467. Australia Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 468. Rest of Asia-Pacific Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 469. Rest of Asia-Pacific Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 470. Rest of Asia-Pacific Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 471. Rest of Asia-Pacific Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 472. Europe Rheumatology Drugs Sales, by Country K Tons (2020-2025)
  • Table 473. Europe Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 474. Europe Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 475. Europe Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 476. Europe Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 477. Germany Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 478. Germany Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 479. Germany Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 480. Germany Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 481. France Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 482. France Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 483. France Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 484. France Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 485. Italy Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 486. Italy Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 487. Italy Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 488. Italy Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 489. United Kingdom Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 490. United Kingdom Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 491. United Kingdom Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 492. United Kingdom Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 493. Netherlands Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 494. Netherlands Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 495. Netherlands Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 496. Netherlands Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 497. Rest of Europe Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 498. Rest of Europe Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 499. Rest of Europe Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 500. Rest of Europe Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 501. MEA Rheumatology Drugs Sales, by Country K Tons (2020-2025)
  • Table 502. MEA Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 503. MEA Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 504. MEA Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 505. MEA Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 506. Middle East Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 507. Middle East Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 508. Middle East Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 509. Middle East Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 510. Africa Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 511. Africa Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 512. Africa Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 513. Africa Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 514. North America Rheumatology Drugs Sales, by Country K Tons (2020-2025)
  • Table 515. North America Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 516. North America Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 517. North America Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 518. North America Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 519. United States Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 520. United States Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 521. United States Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 522. United States Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 523. Canada Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 524. Canada Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 525. Canada Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 526. Canada Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 527. Mexico Rheumatology Drugs Sales, by Type K Tons (2020-2025)
  • Table 528. Mexico Rheumatology Drugs Sales, by Application K Tons (2020-2025)
  • Table 529. Mexico Rheumatology Drugs Sales, by Drug Type K Tons (2020-2025)
  • Table 530. Mexico Rheumatology Drugs Sales, by Route of Administration K Tons (2020-2025)
  • Table 531. Rheumatology Drugs: by Type(USD/Units)
  • Table 532. Research Programs/Design for This Report
  • Table 533. Key Data Information from Secondary Sources
  • Table 534. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Rheumatology Drugs: by Type USD Million (2014-2019)
  • Figure 5. Global Rheumatology Drugs: by Application USD Million (2014-2019)
  • Figure 6. Global Rheumatology Drugs: by Drug Type USD Million (2014-2019)
  • Figure 7. Global Rheumatology Drugs: by Route of Administration USD Million (2014-2019)
  • Figure 8. South America Rheumatology Drugs Share (%), by Country
  • Figure 9. Asia Pacific Rheumatology Drugs Share (%), by Country
  • Figure 10. Europe Rheumatology Drugs Share (%), by Country
  • Figure 11. MEA Rheumatology Drugs Share (%), by Country
  • Figure 12. North America Rheumatology Drugs Share (%), by Country
  • Figure 13. Global Rheumatology Drugs: by Type K Tons (2014-2019)
  • Figure 14. Global Rheumatology Drugs: by Application K Tons (2014-2019)
  • Figure 15. Global Rheumatology Drugs: by Drug Type K Tons (2014-2019)
  • Figure 16. Global Rheumatology Drugs: by Route of Administration K Tons (2014-2019)
  • Figure 17. South America Rheumatology Drugs Share (%), by Country
  • Figure 18. Asia Pacific Rheumatology Drugs Share (%), by Country
  • Figure 19. Europe Rheumatology Drugs Share (%), by Country
  • Figure 20. MEA Rheumatology Drugs Share (%), by Country
  • Figure 21. North America Rheumatology Drugs Share (%), by Country
  • Figure 22. Global Rheumatology Drugs: by Type USD/Units (2014-2019)
  • Figure 23. Global Rheumatology Drugs share by Players 2019 (%)
  • Figure 24. Global Rheumatology Drugs share by Players (Top 3) 2019(%)
  • Figure 25. Global Rheumatology Drugs share by Players (Top 5) 2019(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Takeda Pharmaceutical Company (Japan) Revenue, Net Income and Gross profit
  • Figure 28. Takeda Pharmaceutical Company (Japan) Revenue: by Geography 2019
  • Figure 29. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 30. Sanofi (France) Revenue: by Geography 2019
  • Figure 31. Genentech (United States) Revenue, Net Income and Gross profit
  • Figure 32. Genentech (United States) Revenue: by Geography 2019
  • Figure 33. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 34. Eli Lilly and Company (United States) Revenue: by Geography 2019
  • Figure 35. AbbVie Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. AbbVie Inc. (United States) Revenue: by Geography 2019
  • Figure 37. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 38. Pfizer (United States) Revenue: by Geography 2019
  • Figure 39. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 40. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2019
  • Figure 41. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 42. Novartis (Switzerland) Revenue: by Geography 2019
  • Figure 43. Boehringer Ingelheim GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 44. Boehringer Ingelheim GmbH (Germany) Revenue: by Geography 2019
  • Figure 45. Janssen Biotech (United States) Revenue, Net Income and Gross profit
  • Figure 46. Janssen Biotech (United States) Revenue: by Geography 2019
  • Figure 47. Regeneron Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 48. Regeneron Pharmaceuticals, Inc. (United States) Revenue: by Geography 2019
  • Figure 49. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 50. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2019
  • Figure 51. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 52. Amgen Inc. (United States) Revenue: by Geography 2019
  • Figure 53. Global Rheumatology Drugs: by Type USD Million (2020-2025)
  • Figure 54. Global Rheumatology Drugs: by Application USD Million (2020-2025)
  • Figure 55. Global Rheumatology Drugs: by Drug Type USD Million (2020-2025)
  • Figure 56. Global Rheumatology Drugs: by Route of Administration USD Million (2020-2025)
  • Figure 57. South America Rheumatology Drugs Share (%), by Country
  • Figure 58. Asia Pacific Rheumatology Drugs Share (%), by Country
  • Figure 59. Europe Rheumatology Drugs Share (%), by Country
  • Figure 60. MEA Rheumatology Drugs Share (%), by Country
  • Figure 61. North America Rheumatology Drugs Share (%), by Country
  • Figure 62. Global Rheumatology Drugs: by Type K Tons (2020-2025)
  • Figure 63. Global Rheumatology Drugs: by Application K Tons (2020-2025)
  • Figure 64. Global Rheumatology Drugs: by Drug Type K Tons (2020-2025)
  • Figure 65. Global Rheumatology Drugs: by Route of Administration K Tons (2020-2025)
  • Figure 66. South America Rheumatology Drugs Share (%), by Country
  • Figure 67. Asia Pacific Rheumatology Drugs Share (%), by Country
  • Figure 68. Europe Rheumatology Drugs Share (%), by Country
  • Figure 69. MEA Rheumatology Drugs Share (%), by Country
  • Figure 70. North America Rheumatology Drugs Share (%), by Country
  • Figure 71. Global Rheumatology Drugs: by Type USD/Units (2020-2025)
Some of the key companies/manufacturers profiled in the report
  • Takeda Pharmaceutical Company (Japan)
  • Sanofi (France)
  • Genentech (United States)
  • Eli Lilly and Company (United States)
  • AbbVie Inc. (United States)
  • Pfizer (United States)
  • Bristol-Myers Squibb Company (United States)
  • Novartis (Switzerland)
  • Boehringer Ingelheim GmbH (Germany)
  • Janssen Biotech (United States)
  • Regeneron Pharmaceuticals, Inc. (United States)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Amgen Inc. (United States)
Additional players considered in the study are as follows:
Merck & Co., Inc. (United States) , UCB S.A. (Belgium)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation